News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
NOTA DE PRENSA ORYZON
ORYZON announces submission of Phase III protocol to FDA to initiate PORTICO-2 trial of vafidemstat in Borderline Personality Disorder (BPD) patients
Healthcare · Access to innovation
PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients.
Partners - Oryzon Genomics
GENESIS
GENESIS Biomed participated in the valuation of CellsIA, a company acquired by Laboratorios ROVI.
Healthcare · Access to innovation
GENESIS Biomed provides specialised services in the valuation and search for licensees or acquirers…
Partners - GENESIS Biomed
cara de colores
ORYZON to attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
Corporate
Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives…
Partners - Oryzon Genomics
becytes
BeCytes opens new laboratory to accelerate the production of in vitro cellular models
Healthcare · Access to innovation
BeCytes Biotechnologies, a company specialized in the research and development of in vitro cellular…
Partners - BeCytes Biotechnologies
Patrick Tresserras, CEO y Maria Gallo COO de Disrupt Therapeutics
#NewAseBioMember| "We also see AseBio as an opportunity to stay aligned with regulatory, scientific, and market trends, while raising awareness around an emerging health challenge that demands both attention and action"
Healthcare · Communication · Corporate
Meet our new member Disrupt Therapeutics. We spoke with Patrick Tresserras, CEO y…
Partners - DISRUPT THERAPEUTICS
Dr. Carles Domènech, CEO y cofundador de AbilityPharma
AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer
Healthcare · Innovative drugs · Advanced therapies
These results support ibrilatazar as a potential backbone therapy for patients with one of the most…
Partners - Ability Pharmaceuticals
Reunión de equipo valorando resultados económicos
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
Healthcare · Access to innovation
Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory…
Partners - THERIVA BIOLOGICS S.L.
BCN HEALTH publica un estudio que pone de relieve los elevados costes sanitarios asociados al carcinoma hepatocelular en España
BCN HEALTH publishes a study highlighting the substantial healthcare costs associated with hepatocellular carcinoma in Spain
Healthcare · Access to innovation
BCN HEALTH has published the study ‘Hepatocellular carcinoma: what are the differential costs…
Partners - BCN Health
N-GENE
Genetics Becomes an Ally for Healthcare Professionals
Healthcare · Access to innovation · Digitalization
Personalized medicine is no longer a promise—it's a reality, with genetics as its key ally. To…
Partners - ADNTRO GENETICS SL